Burosumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Burosumab and local guidelines before prescribing.
Anti-FGF23 antibody
Mechanism
Anti-FGF23 monoclonal antibody.
Uses
X-linked hypophosphataemia, tumour-induced osteomalacia.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reactions, hyperphosphataemia, headache.
Interactions
Phosphate supplements and active vitamin D contraindicated.
Contraindications and cautions
Severe renal impairment
Monitoring
Phosphate, PTH
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Contraindicated in severe renal impairment
Overdose and reversal
Supportive
Special advice
Monitor phosphate and calcium.
More from the textbook: uses, cautions and other points
- Burosumab (an anti-FGF23 antibody) - NICE recommends it for children and young people with radiographic evidence of bone disease (HST8).
Endocrinology: Bone Medicine - Burosumab | Anti-FGF23 antibody for X-linked hypophosphataemia in children and young people (NICE HST8).
Endocrinology: Bone Medicine - FGF-23 excess - X-linked hypophosphataemia (treated with burosumab), tumour-induced osteomalacia.
Renal: Tubular Inherited Stones - Other types - X-linked hypophosphataemic rickets (low phosphate, normal vitamin D - burosumab), renal rickets (CKD).
Paediatrics: Growth, development and nutrition
Where it is discussed in the book
- Endocrinology: Bone Medicine (2 mentions)
- Renal: Tubular Inherited Stones (1 mention)
- Paediatrics: Growth, development and nutrition (1 mention)
- Integrated paediatrics chapter (1 mention)